[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0904273T3 - Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist - Google Patents

Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist

Info

Publication number
DK0904273T3
DK0904273T3 DK97907237T DK97907237T DK0904273T3 DK 0904273 T3 DK0904273 T3 DK 0904273T3 DK 97907237 T DK97907237 T DK 97907237T DK 97907237 T DK97907237 T DK 97907237T DK 0904273 T3 DK0904273 T3 DK 0904273T3
Authority
DK
Denmark
Prior art keywords
dipamine
benzisothiazol
ziprasidone
indol
piperazinyl
Prior art date
Application number
DK97907237T
Other languages
Danish (da)
English (en)
Inventor
Frank R Busch
Carol A Rose
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0904273T3 publication Critical patent/DK0904273T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK97907237T 1996-05-07 1997-03-26 Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist DK0904273T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07
PCT/IB1997/000306 WO1997042190A1 (en) 1996-05-07 1997-03-26 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (1)

Publication Number Publication Date
DK0904273T3 true DK0904273T3 (da) 2003-07-07

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97907237T DK0904273T3 (da) 1996-05-07 1997-03-26 Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist

Country Status (46)

Country Link
US (1) US6110918A (xx)
EP (1) EP0904273B1 (xx)
JP (1) JP3102896B2 (xx)
KR (1) KR100333214B1 (xx)
CN (1) CN1092658C (xx)
AP (1) AP838A (xx)
AR (1) AR007003A1 (xx)
AT (1) ATE236902T1 (xx)
AU (1) AU730856C (xx)
BG (1) BG63601B1 (xx)
BR (1) BR9708932A (xx)
CA (1) CA2252895C (xx)
CO (1) CO4940465A1 (xx)
CZ (1) CZ289216B6 (xx)
DE (1) DE69720719T2 (xx)
DK (1) DK0904273T3 (xx)
DZ (1) DZ2221A1 (xx)
EA (1) EA001180B1 (xx)
EG (1) EG24401A (xx)
ES (1) ES2192264T3 (xx)
GT (1) GT199700042A (xx)
HK (1) HK1017893A1 (xx)
HN (1) HN1997000040A (xx)
HR (1) HRP970235B1 (xx)
HU (1) HU229057B1 (xx)
ID (1) ID17504A (xx)
IL (1) IL126590A (xx)
IS (1) IS2301B (xx)
MA (1) MA26427A1 (xx)
ME (1) ME00901B (xx)
MY (1) MY128051A (xx)
NO (1) NO312513B1 (xx)
NZ (2) NZ508303A (xx)
OA (1) OA10908A (xx)
PL (1) PL188164B1 (xx)
PT (1) PT904273E (xx)
SI (1) SI0904273T1 (xx)
SK (1) SK282674B6 (xx)
TN (1) TNSN97073A1 (xx)
TR (1) TR199802241T2 (xx)
TW (1) TW427989B (xx)
UA (1) UA47467C2 (xx)
UY (1) UY24543A1 (xx)
WO (1) WO1997042190A1 (xx)
YU (1) YU49398B (xx)
ZA (1) ZA973875B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
ES2204067T3 (es) * 1998-05-26 2004-04-16 Pfizer Products Inc. Medicamento para el tratamiento del glaucoma y de la retinopatia isquemica.
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
SI1468686T1 (sl) * 2000-06-02 2007-04-30 Pfizer Prod Inc S-metil-dihidro-ziprazidon za zdravljenje psihiatricnih motenj
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
WO2004100955A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2004100954A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
CA2528100A1 (en) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Polymorphic forms of ziprasidone hcl and processes for their preparation
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CA2550485A1 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
US20080312254A1 (en) * 2004-02-27 2008-12-18 Ranbaxy Laboratories Limited Process for the Preparation of Ziprasidone
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
TNSN97073A1 (fr) 2005-03-15
DE69720719D1 (de) 2003-05-15
SK282674B6 (sk) 2002-11-06
OA10908A (en) 2001-10-26
EP0904273A1 (en) 1999-03-31
TW427989B (en) 2001-04-01
MA26427A1 (fr) 2004-12-20
EA199800909A1 (ru) 1999-04-29
SK150598A3 (en) 2000-03-13
UA47467C2 (uk) 2002-07-15
ATE236902T1 (de) 2003-04-15
NZ508303A (en) 2001-07-27
IL126590A0 (en) 1999-08-17
HK1017893A1 (en) 1999-12-03
CZ349498A3 (cs) 1999-09-15
NO985193D0 (no) 1998-11-06
AP9700978A0 (en) 1997-07-31
BG63601B1 (bg) 2002-06-28
NZ332219A (en) 2005-02-25
ME00901B (me) 2005-11-28
EP0904273B1 (en) 2003-04-09
EG24401A (en) 2009-04-29
UY24543A1 (es) 2000-09-29
ID17504A (id) 1998-01-08
HN1997000040A (es) 1997-06-05
AP838A (en) 2000-05-03
ZA973875B (en) 1998-11-06
IL126590A (en) 2001-11-25
KR20000010822A (ko) 2000-02-25
HUP9902808A2 (hu) 2000-03-28
NO312513B1 (no) 2002-05-21
CA2252895C (en) 2002-08-20
ES2192264T3 (es) 2003-10-01
HU229057B1 (en) 2013-07-29
DE69720719T2 (de) 2003-11-06
HUP9902808A3 (en) 2000-04-28
IS4878A (is) 1998-10-23
PL188164B1 (pl) 2004-12-31
EA001180B1 (ru) 2000-10-30
YU49398B (sh) 2005-11-28
CZ289216B6 (cs) 2001-12-12
YU17397A (sh) 2000-10-30
CN1216990A (zh) 1999-05-19
PT904273E (pt) 2003-06-30
BR9708932A (pt) 1999-08-03
AR007003A1 (es) 1999-10-13
KR100333214B1 (ko) 2002-06-20
BG102893A (en) 1999-09-30
CA2252895A1 (en) 1997-11-13
TR199802241T2 (xx) 1999-02-22
SI0904273T1 (en) 2003-08-31
GT199700042A (es) 1998-10-02
CO4940465A1 (es) 2000-07-24
AU1936897A (en) 1997-11-26
PL329880A1 (en) 1999-04-12
WO1997042190A1 (en) 1997-11-13
IS2301B (is) 2007-10-15
JPH11509865A (ja) 1999-08-31
CN1092658C (zh) 2002-10-16
HRP970235B1 (en) 2002-08-31
US6110918A (en) 2000-08-29
AU730856C (en) 2001-11-15
AU730856B2 (en) 2001-03-15
MY128051A (en) 2007-01-31
JP3102896B2 (ja) 2000-10-23
DZ2221A1 (fr) 2002-12-03
NO985193L (no) 1998-11-06
HRP970235A2 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
DK0904273T3 (da) Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
NO985194D0 (no) Mesylat-dihydratsalter av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2(1H)-indol-2-on(ziprazidone), fremstilling derav og anvendelse derav som dopamin D2 antagonist
NO933093L (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2H-indol-2-on hydroklorid
PT1349855E (pt) Sal misilato de 5-{4-[2-(n-metil-n-(2-piridil)amino)etoxi]benzil}tiazolidino-2, 4-diona
DK1556378T3 (da) Acylderivater af 5-(2-(4-(1,2 benzisothiazol-3-yl)-1piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indo-2-on med neuroleptisk aktivitet
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo